Treatment of Drug-Resistant Tuberculosis
Open accessAbstract
The treatment of drug-resistant tuberculosis (TB) is complicated and has evolved significantly in the past decade with the advent of rapid molecular tests and updated evidence-based guidelines of the World Health Organization and other organizations. The latest recommendations incorporate the use of new drugs and regimens that maximize efficacy and minimize toxicity to improve treatment outcomes for the patients. This article provides an overview of the latest published strategies for clinical and programmatic management of drug-resistant TB.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment typically involves standard antitubercular therapy, which is effective in most cases, although multidrug-resistant TB can complicate treatment.
“Treatment typically involves standard antitubercular therapy, which is effective in most cases, although multidrug-resistant TB can complicate treatment [32,33,34].”
From Head and Neck Tuberculosis: A Rare Diagnosis and the Role of Surgical Biopsy and Histopathological Evaluation in Extrapulmonary Disease (2025) · cites this paper as [33]
The Introduction > Background (page not available) identifies four drugs commonly used for drug-susceptible TB and says multidrug-resistant TB requires longer treatment with less effective, more toxic second-line drugs. This supports the treatment complication, but the paper does not state that standard therapy is effective in most cases. (LLM, conf=0.83)
Experimental — accuracy not yet measuredCoexistence of TB and carcinoma in the same patient is a rare situation reported in the literature.
“Another aspect that clinicians must not disregard is the coexistence of TB and carcinoma in the same patient, several cases being reported in the literature [20,33] regarding this particularly rare situation.”
From Head and Neck Tuberculosis: A Rare Diagnosis and the Role of Surgical Biopsy and Histopathological Evaluation in Extrapulmonary Disease (2025) · cites this paper as [33]
The Comorbid Conditions section discusses diabetes, tobacco use, alcoholism, and drug use, but not carcinoma. Searches for TB–carcinoma coexistence and cancer-related terms found no passage in our copy addressing reported cases or their rarity. Page numbers were not available. (LLM, conf=0.72)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 1× · see citing works
“…is available, treatment decisions must be guided largely by expert opinion, rather than through recommendations developed through the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology 21,22 because of the paucity of available data to inform such a process.”
BackgroundGlobal tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702 · see citing works
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brożek, J., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,492 · see citing works
Dheda, K. U. J., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M. B., Furin, J. J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 686 · see citing works
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 634 · see citing works
Self-citationSchünemann, H. J., Jaeschke, R., Cook, D. J., Bria, W. F., El-Solh, A. A., Ernst, A., Fahy, B. F., Gould, M. K., Horan, K. L., Krishnan, J. A., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-197st · Cited by 577 · see citing works
Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M. V., Centis, R., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001300 · Cited by 532 · see citing works
Therapeutic Drug Monitoring in the Treatment of Tuberculosis
Peloquin, C. A. (2002) · Drugs · doi:10.2165/00003495-200262150-00001 · Cited by 447 · see citing works
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Nunn, A., Phillips, P. P. J., Meredith, S. K., Chiang, C., Conradie, F., Dalai, D., Deun, A. V., Dat, P. T., Lan, N., Master, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811867 · Cited by 389 · see citing works
Falzon, D., Gandhi, N. R., Migliori, G. B., Sotgiu, G., Cox, H. S., Holtz, T. H., Hollm-Delgado, M.-G., Keshavjee, S. A., DeRiemer, K., Centis, R., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00134712 · Cited by 385 · see citing works
Guidelines for treatment of drug-susceptible tuberculosis and patient care-2017 update
Gao, J., Wang, X., Fu, L., & Du, J. (2018) · Chinese Journal of Asthma · doi:10.3760/cma.j.issn.1673-436x.2018.03.001 · Cited by 231 · see citing works
Cerebrospinal fluid concentrations of antituberculosis agents in adults and children
Donald, P. R. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.07.002 · Cited by 222 · see citing works
von Groote-Bidlingmaier, F., Patientia, R. F., Sánchez, E., Balanag, V. M., Ticona, E., Segura, P., Cadena, E., Yu, C. Y., Cīrule, A., Lizarbe, V., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30426-0 · Cited by 171 · see citing works
Harausz, E., Garcia‐Prats, A. J., Law, S. J., Schaaf, H. S., Kredo, T., Seddon, J. A., Menzies, D., Turkova, A., Achar, J., Amanullah, F., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002591 · Cited by 152 · see citing works
Marks, S. M., Mase, S., & Morris, S. B. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix208 · Cited by 123 · see citing works
Self-citationSirgel, F. A., Warren, R. M., Streicher, E. M., Victor, T. C., van Helden, P. D., & Böttger, E. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks033 · Cited by 117 · see citing works
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis
Bastos, M. L., Lan, Z., & Menzies, D. (2017) · European Respiratory Journal · doi:10.1183/13993003.00803-2016 · Cited by 115 · see citing works
Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012
Bamrah, S., Brostrom, R. J., Fred, D., Setik, L., Song, R., Kawamura, L. M., Heetderks, A., & Mase, S. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0028 · Cited by 113 · see citing works
Self-citationKhan, F. A., Salim, M. S., du Cros, P., Casas, E. C., Khamraev, A., Sikhondze, W., Benedetti, A., Bastos, M. L., Lan, Z., Jaramillo, E., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00061-2017 · Cited by 110 · see citing works
Fregonese, F., Ahuja, S. D., Akkerman, O. W., Arakaki-Sánchez, D., Ayakaka, I., Baghaei, P., Bang, D., Bastos, M. L., Benedetti, A., Bonnet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30078-x · Cited by 110 · see citing works
Fox, G. J., Mitnick, C. D., Benedetti, A., Chan, E. D., Becerra, M. C., Chiang, C., Keshavjee, S. A., Koh, W., Shiraishi, Y., Viiklepp, P., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw002 · Cited by 82 · see citing works
Marrone, M. T., Venkataramanan, V., Goodman, M. G., Hill, A. C., Jereb, J., & Mase, S. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0198 · Cited by 78 · see citing works
Self-citationTranslational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions
Lienhardt, C., Lönnroth, K., Menzies, D., Balasegaram, M., Chakaya, J. M., Cobelens, F. G. J., Cohn, J., Denkinger, C. M., Evans, T. G., Källenius, G., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001965 · Cited by 70 · see citing works
Blassmann, U., Roehr, A. C., Frey, O. R., Vetter‐Kerkhoff, C., Thon, N., Hope, W. W., Briegel, J., & Huge, V. (2016) · Critical Care · doi:10.1186/s13054-016-1523-y · Cited by 69 · see citing works
Meng, L., Huang, J., Jia, Y., Huang, H., Qiu, F., & Sun, S. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13331 · Cited by 67 · see citing works
Seddon, J. A., Garcia‐Prats, A. J., Purchase, S. E., Osman, M., Demers, A., Hoddinott, G., Crook, A. M., Owen-Powell, E., Thomason, M. J., Turkova, A., et al. (2018) · Trials · doi:10.1186/s13063-018-3070-0 · Cited by 64 · see citing works
Gupta, A., Mathad, J. S., Abdel‐Rahman, S. M., Albano, J. D., Botgros, R., Brown, V., Browning, R., Dawson, L., Dooley, K. E., Gnanashanmugam, D., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ991 · Cited by 63 · see citing works
Priorities for tuberculosis research: a systematic review
Rylance, J., Pai, M., Lienhardt, C., & Garner, P. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70201-2 · Cited by 60 · see citing works
Linezolid Penetration Into Cerebrospinal Fluid and Brain Tissue
Tsona, A., Metallidis, S., Foroglou, N., Selviaridis, P., Chrysanthidis, T., Lazaraki, G., Papaioannou, M., Nikolaidis, J., & Nikolaidis, P. (2010) · Journal of Chemotherapy · doi:10.1179/joc.2010.22.1.17 · Cited by 48 · see citing works
Evolution of Programmatic Definitions Used in Tuberculosis Prevention and Care
Migliori, G. B., & Global Tuberculosis Network (GTN) (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy990 · Cited by 29 · see citing works
Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis
Sterling, T. R. (2016) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0117 · Cited by 14 · see citing works
Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic
Reid, M. J. A., & Goosby, E. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix373 · Cited by 14 · see citing works
Editorial Response: Multidrug‐Resistant Tuberculosis–Globally with Us for the Long Haul
Salomon, N., & Perlman, D. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520188 · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [14]World Health Organization. WHO consolidated guidelines on guidelines on drug-resistant tuberculosis treatment. Geneva (Switzerland): World Health Organization; 2019 Available at: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/. 30946559
- [17]Curry International Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 3rd edition San Francisco (CA): Francis C Curry International Tuberculosis Center; 2016.
- [33]World Health Organization. Companion Handbook to the WHO guidelines for programmatic management of drug-resistant tuberculosis. Geneva (Switzerland): World Health Organization; 2014 Available at: https://www.ncbi.nlm.nih.gov/books/NBK247420/pdf/Bookshelf_NBK247420.pdf. 25320836
Cited by
Sorted by citations
Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance
Gopalaswamy, R., Dusthackeer, A., Kannayan, S., & Subbian, S. (2021) · Journal of Respiration · doi:10.3390/jor1020015 · Cited by 173 · see citing works
Drug-Resistant Tuberculosis 2020: Where We Stand
Iacobino, A., Fattorini, L., & Giannoni, F. (2020) · Applied Sciences · doi:10.3390/app10062153 · Cited by 69 · see citing works
Gastrointestinal and Abdominal Tuberculosis
Eraksoy, H. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.02.004 · Cited by 66 · see citing works
Chowdhury, K., Ahmad, R., Sinha, S., Dutta, S., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.35154 · Cited by 50 · see citing works
Borah, P., Deb, P. K., Venugopala, K. N., Al‐Shar’i, N. A., Singh, V., Deka, S., Srivastava, A., Tiwari, V. K., & Mailavaram, R. P. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621999201211200447 · Cited by 48 · see citing works
Umare, M. D., Khedekar, P. B., & Chikhale, R. V. (2021) · ChemMedChem · doi:10.1002/cmdc.202100359 · Cited by 47 · see citing works
Current advances in the clinical development of anti-tubercular agents
Tetali, S. R., Kunapaeddi, E., Mailavaram, R. P., Singh, V., Borah, P., Deb, P. K., Venugopala, K. N., Hourani, W., & Tekade, R. K. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.101989 · Cited by 45 · see citing works
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Sweeney, S., Berry, C., Kazounis, E., Motta, I., Vassall, A., Dodd, M., Fielding, K., & Nyang’wa, B.-T. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001337 · Cited by 37 · see citing works
Pecora, F., Canto, G. D., Veronese, P., & Esposito, S. (2021) · Microorganisms · doi:10.3390/microorganisms9051074 · Cited by 31 · see citing works
Habjan, E., Ho, V. Q. T., Gallant, J., van Stempvoort, G., Jim, K. K., Kuijl, C. P., Geerke, D. P., Bitter, W., & Speer, A. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049145 · Cited by 31 · see citing works
An updated patent review on drugs for the treatment of tuberculosis (2018-present)
Ahmed, S., Nandi, S., & Saxena, A. K. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2012151 · Cited by 27 · see citing works
Valencia, J., Rubio, V. V., Puerto, G., Vasquez, L., Bernal, A., Mora, J. R., Cuesta, S. A., Paz, J. L., Braulio Insuasty, O., Abonı́a, R., et al. (2022) · Antibiotics · doi:10.3390/antibiotics12010061 · Cited by 25 · see citing works
Vilchèze, C., & Jacobs, W. R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01703-20 · Cited by 23 · see citing works
Panford, V., Kumah, E., Kokuro, C., Adoma, P. O., Baidoo, M. A., Fusheini, A., Ankomah, S. E., Agyei, S. K., & Agyei‐Baffour, P. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062857 · Cited by 21 · see citing works
Are all antibiotic persisters created equal?
Shultis, M. W., Mulholland, C. V., & Berney, M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.933458 · Cited by 19 · see citing works
Triblock copolymeric drug delivery as an emerging nanocarrier for treatment of infectious diseases
Singh, V., Eljaaly, K., Md, S., Alhakamy, N. A., & Kesharwani, P. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103691 · Cited by 19 · see citing works
Shukla, S., Rao, R. N., Bhuktar, H., Edwin, R. K., Trinath, J., Medishetti, R., Banerjee, S., Giliyaru, V. B., Shenoy, G. G., Oruganti, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106452 · Cited by 18 · see citing works
Patel, M. N., Patel, A. J., Nandpal, M. N., Raval, M., Patel, R. J., Patel, A. A., Paudel, K. R., Hansbro, P. M., Singh, S. K., Gupta, G., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03466-0 · Cited by 18 · see citing works
Evans, D. H., Hirasen, K., Ramushu, C., Long, L. C., Sinanovic, E., Conradie, F., Howell, P., Padanilam, X., Ferreira, H., Variaiva, E., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309034 · Cited by 17 · see citing works
Lazarus, G., Tjoa, K., Iskandar, A. W. B., Louisa, M., Sagwa, E., Padayatchi, N., & Soetikno, V. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248017 · Cited by 17 · see citing works
Safety of prolonged treatment with bedaquiline in programmatic conditions
Zhurkin, D., Gurbanova, E., Campbell, J. R., Menzies, D., Setkina, S., Hurevich, H., Solodovnikova, V., Viatushka, D., Altraja, A., & Skrahina, A. M. (2022) · ERJ Open Research · doi:10.1183/23120541.00685-2021 · Cited by 16 · see citing works
Briffotaux, J., Xu, Y., Huang, W., Hui, Z., Wang, X., Gicquel, B., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27207130 · Cited by 16 · see citing works
Fâcă, A. I., Udeanu, D. I., Arsene, A. L., Mahler, B., Drăgănescu, D., & Apetroaei, M.-M. (2025) · Nutrients · doi:10.3390/nu17111878 · Cited by 21 · see citing works
Karnan, A., Jadhav, U. S., Ghewade, B., Ledwani, A., & Shivashankar, P. (2024) · Cureus · doi:10.7759/cureus.52706 · Cited by 15 · see citing works
Shanmuga Priya, K., Mani, A. P., Geethalakshmi, S., & Yadav, S. (2024) · Cureus · doi:10.7759/cureus.60280 · Cited by 15 · see citing works
Kósa, N., Zolcsák, Á., Voszka, I., Csı́k, G., Horváti, K., Horváth, L. B., Bősze, S. E., & Herényi, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052457 · Cited by 13 · see citing works
Thongdee, P., Hanwarinroj, C., Pakamwong, B., Kamsri, P., Punkvang, A., Leanpolchareanchai, J., Ketrat, S., Saparpakorn, P., Hannongbua, S., Ariyachaokun, K., et al. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00531 · Cited by 13 · see citing works
Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study
Du, L., Zhang, Y., Lv, X., Duan, Y., Shi, X., Ji, H., Wu, R., Xu, J. Y., Chen, X., Gao, Y., et al. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s294611 · Cited by 13 · see citing works
Managing Hepatotoxicity Caused by Anti-tuberculosis Drugs: A Comparative Study of Approaches
Abbaspour, F., Hasannezhad, M., Khalili, H., SeyedAlinaghi, S., & Jafari, S. (2024) · Archives of Iranian Medicine · doi:10.34172/aim.2024.19 · Cited by 12 · see citing works
Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation
Visca, D., Tiberi, S., Centis, R., D’Ambrosio, L., Pontali, E., Mariani, A. W., Zampogna, E., van den Boom, M., Spanevello, A., & Migliori, G. B. (2020) · Applied Sciences · doi:10.3390/app10082734 · Cited by 12 · see citing works
Tuberculosis: An Ongoing Global Threat
Farnia, P., Velayati, A. A., Ghanavi, J., & Farnia, P. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-96883-9_1 · Cited by 16 · see citing works
Duga, A. L., Salvo, F., Kay, A. W., & Figueras, A. (2023) · Antibiotics · doi:10.3390/antibiotics12050811 · Cited by 11 · see citing works
Patel, A., Pundkar, A., Agarwal, A., Gadkari, C. P., Nagpal, A. K., & Kuttan, N. (2024) · Cureus · doi:10.7759/cureus.68784 · Cited by 11 · see citing works
Addu, N., Miriyala, H., Kapavarapu, R., Kolli, S. K., & Pal, M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135313 · Cited by 11 · see citing works
Mahnashi, M. H., Koganole, P., R., P. K. S., Ashgar, S. S., Shaikh, I. A., Joshi, S. D., & Alqahtani, A. S. (2023) · Antibiotics · doi:10.3390/antibiotics12040763 · Cited by 11 · see citing works
Wu, L., Chang, W., Song, Y., & Wang, L. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.035 · Cited by 10 · see citing works
Rodríguez-García, Á., Mares‐Alejandre, R. E., Muñoz-Muñoz, P. L. A., Ruvalcaba-Ruiz, S., González-Sánchez, R., Bernáldez-Sarabia, J., Meléndez-López, S. G., Licea-Navarro, A. F., & Ramos, M. A. (2021) · Antibiotics · doi:10.3390/antibiotics10070807 · Cited by 9 · see citing works
Verma, A., Naik, B., Kumar, V., Mishra, S., Choudhary, M., Khan, J. M., Gupta, A. K., Pandey, P., Rustagi, S., Kakati, B., et al. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00436 · Cited by 8 · see citing works
Anh, N. K., Yen, N. T. H., Tien, N. T. N., Phat, N. K., Park, Y. J., Kim, H.-S., Vu, D. H., Oh, J. Y., Kim, D., & Long, N. P. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167064 · Cited by 8 · see citing works
Fluoroquinolones for the Treatment of Tuberculosis: An Overview
Jain, S. D., Prachand, S., Gupta, A., & Jain, S. R. (2023) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2023.00057 · Cited by 7 · see citing works
Design and synthesis of benzimidazole derivatives as antimycobacterial agents
Sindhu, G., Kholiya, R., Kidwai, S., Singh, P., Singh, R., & Rawat, D. S. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23123 · Cited by 7 · see citing works
Drug-resistance and its impact on cutaneous tuberculosis
Ramesh, V., Bhandari, A., & Mahajan, R. (2022) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_27_22 · Cited by 7 · see citing works
Kim, H.-J., Lee, S.-Y., Jo, E., Kim, H., Kim, H., Kim, E.-G., Kwon, S., & Shin, S. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11446-0 · Cited by 6 · see citing works
Yadav, S. (2022) · Cureus · doi:10.7759/cureus.32963 · Cited by 6 · see citing works
Al-Karawi, A. S., Kadhim, A. A., & Kadum, M. M. (2024) · International Journal of Clinical Biochemistry and Research · doi:10.18231/j.ijcbr.2023.048 · Cited by 6 · see citing works
Harnessing CRISPR-Cas9 as an anti-mycobacterial system
Sodani, M., Misra, C. S., Rath, D., & Kulkarni, S. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127319 · Cited by 5 · see citing works
Shi, J., Zheng, D., Su, R., Ma, X.-G., Zhu, Y., Wang, S., Chang, W., & Sun, D. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10730-y · Cited by 5 · see citing works
Wei, X., Norsuddin, N. M., Hamid, H. A., Azmi, M. I., Zhang, G., & Tian, J. (2025) · Health Science Reports · doi:10.1002/hsr2.71350 · Cited by 4 · see citing works
Bhavani, G. V., Kondapuram, S. K., Fathima, A., Coumar, M. S., Selvin, J., & Kannan, T. (2023) · Drug Development Research · doi:10.1002/ddr.22039 · Cited by 4 · see citing works
Rational use of antibiotics—Save antibiotics for future generations
Sarethy, I. P., Srivastava, N., Chaturvedi, S., Chauhan, N., & Danquah, M. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95388-7.00023-1 · Cited by 4 · see citing works
Li, S., Chen, W. L., Feng, M., Liu, Y., & Wang, F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12122088 · Cited by 4 · see citing works
Multitargeting: An Alternative Approach to Tackle Multidrug Resistance in Tuberculosis
Hazra, S., Hazarika, R., & Patra, S. (2023) · Current Drug Targets · doi:10.2174/1389450124666230505145335 · Cited by 4 · see citing works
Platforms for Personalized Polytherapeutics Discovery in COVID-19
Hopkins, C. E., Onweni, C. L., Zambito, V., Fairweather, D., McCormick, K., Ebihara, H., Caulfield, T. R., Zhang, Y. S., & Freeman, W. D. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166945 · Cited by 4 · see citing works
Development of machine learning models to identify potentially active compounds against tuberculosis
Rawat, A., Gupta, S., Pal, C., & Chowdhury, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-04668-z · Cited by 3 · see citing works
Rathored, J., Budhbaware, T., Shende, S., & Upadhyay, V. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1692281 · Cited by 3 · see citing works
Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil
da Costa, F. B. P., Berra, T. Z., Ballestero, J. G. D. A., Oliveira, P. B., Pelissari, D. M., Alves, Y. M., Ramos, A. C. V., de Paiva, J. Q. R., Teibo, T. K. A., & Arcêncio, R. A. (2023) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2023.100388 · Cited by 3 · see citing works
Nano vs Resistant Tuberculosis: Taking the Lung Route
Sharma, D., Pooja, P., Nirban, S., Ojha, S., Kumar, T., Jain, N., Mohamad, N., Kumar, P., & Pandey, M. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02708-3 · Cited by 3 · see citing works
Kumar, B. S., Rao, L. V., Dhananjaya, G., Kapavarapu, R., & Pal, M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139931 · Cited by 3 · see citing works
Brintha, V. P., & Narayanan, M. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf139 · Cited by 3 · see citing works
Focus on perchlozone, an anti-tuberculosis drug from the Russian Federation
Malík, I., Cizmárik, J., & Pecháčová, M. (2020) · Česká a slovenská farmacie · doi:10.36290/csf.2020.028 · Cited by 3 · see citing works
Mogoantă, C. A., Osman, A., Georgescu, A.-M., Mitroi, A. M., Busuioc, C. I., Tănase, I., Cioboată, R., Liliac, I. M., Cimpeanu, O. L., & Ciolofan, M. S. (2025) · Pathogens · doi:10.3390/pathogens14050479 · Cited by 2 · see citing works
“Another aspect that clinicians must not disregard is the coexistence of TB and carcinoma in the same patient, several cases being reported in the literature [20,33] regarding this particularly rare situation.”
Gnanavelou, R., Perinbaraj, S., & Girija, K. R. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638362095250402180030 · Cited by 2 · see citing works
Alamri, A., Alafnan, A., Hussein, W., Almansour, K., Alrafidi, R. D., & Abouzied, A. S. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00626-z · Cited by 2 · see citing works
Synthesis, Docking and In Vitro Evaluation of Spiroindoline‐3,2’‐Quinazoline Derivatives
Addu, N., Miriyala, H., Kapavarapu, R., Kolli, S. K., & Pal, M. (2023) · ChemistrySelect · doi:10.1002/slct.202302793 · Cited by 2 · see citing works
Prevalence and Genetic Analysis of Isoniazid-Resistant Tuberculosis in Eastern Uttar Pradesh, India
Singh, N., Singh, A. K., Sarita, S., Kumar, S., Mishra, A. K., & Singh, N. P. (2025) · Cureus · doi:10.7759/cureus.80243 · Cited by 2 · see citing works
Franco, P. D., Galan, S. J. P., Manguba, P. C. D., Sibug, M. I. T., & Manlutac, J. M. D. (2023) · International Journal of Research Publications · doi:10.47119/ijrp1001301820235388 · Cited by 2 · see citing works
Rifampicin-resistant Tuberculosis: A Global Health Dilemma
Ahmad, R., Sinha, S., Chowdhury, K., & Haque, M. (2024) · Advances in Human Biology · doi:10.4103/aihb.aihb_15_24 · Cited by 2 · see citing works
Inflammasome activation dictates the efficacy of antimycobacterial activity of frontline TB drugsPreprint
Rao, V., Singh, A., Bisht, K., Yadav, N., & Nanda, R. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.02.646750 · Cited by 2 · see citing works
Agarwal, N., Gogoi, H., Eeba, E., Augustin, L., Khan, M. Y., Kumar, Y., Bhowmick, S. K., & Dey, B. (2025) · eLife · doi:10.7554/elife.107025.1 · Cited by 2 · see citing works
Global Impact of Tuberculosis and HIV coinfection
Nigam, A., Mukherjee, U., & Verma, M. (2022) · Microsphere · doi:10.59118/jsst1347 · Cited by 1 · see citing works
Shivanoori, J., Baldha, M., Kolli, S. K., Kapavarapu, R., & Pal, M. (2025) · Tetrahedron Green Chem · doi:10.1016/j.tgchem.2025.100080 · Cited by 1 · see citing works
Sardar, Z., Kim, C. Y., Roberts, J. A., Bano, S., & Thakur, K. T. (2025) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2025.06.010 · Cited by 1 · see citing works
Molecular insights of drug-resistant tuberculosis: genetic mutations and their profile
Singh, A. K., Singh, N., Kumar, S., Mishra, A. K., & Singh, N. P. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1669327 · Cited by 1 · see citing works
Sebastian, J., Ma, S., Rustad, T. R., Bustad, E., Thomas, A., Singh, S., Kumar, P., Sherman, D. R., & Alland, D. (2025) · Nature Communications · doi:10.1038/s41467-025-67152-2 · Cited by 1 · see citing works
Bereda, G. (2022) · Journal of Lung Pulmonary & Respiratory Research · doi:10.15406/jlprr.2022.09.00279 · Cited by 1 · see citing works
Drug Discovery and Computational Strategies in Multi-Drug-Resistant Tuberculosis
Satish, S., Joshi, N., Alavala, R. R., & Khan, A. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_26 · Cited by 1 · see citing works
Akalu, G. T., Tessema, B., Sinshaw, W., Amare, M., Diriba, G., Getu, M., Zerihun, B., & Petros, B. (2023) · medRxiv · doi:10.1101/2023.04.20.23288854 · Cited by 1 · see citing works
Ishola, O., Ogunbowale, A., Islam, M. M., Hadadianpour, E., Majeed, S., Adetuyi, O. A., & Georgieva, E. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.26.546575 · Cited by 1 · see citing works
Nurfadilah, N., Djabir, Y. Y., Aminah, S., Patimang, Y. C., Santoso, A., & Yulianty, R. (2022) · Iranian Journal of Toxicology · doi:10.32598/ijt.16.4.854.2
Anti-Tuberculosis Therapy in The Drug Resistant Tuberculosis Patients of Kashmir Valley
Puttoo, A. N., Tripathi, S., Shah, N. N., Nazir, R., Bashir, H., Azad, A. M.-U.-D., Kauser, R., & Inam-Ul-Haq (2022) · International Journal of Life Science and Pharma Research · doi:10.22376/ijlpr.2023.13.1.l281-292
Frequency of Mycobacterium tuberculosis in Pneumonia Patients and Prevalence of Virulence Genes
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.1081
Joshi, T., Nain, P., Bhamra, P., & Kaur, J. (2023) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2023.09.011
Addu, N., Miriyala, H., Kapavarapu, R., Kolli, S. K., & Pal, M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137345
Resistant Tuberculosis: A Comprehensive Health Predicament
Sinha, S., Ahmad, R., Chowdhury, K., & Haque, M. (2024) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v23i2.72091
Characteristics of and treatment outcomes in rifampicin-intolerant patients
Mangat, R., Brode, S. K., Mah, H. K.-H., Brar, M. S., & Sabur, N. F. (2024) · IJTLD OPEN · doi:10.5588/ijtldopen.23.0466
Overview of Anti-Tuberculosis Treatment Compliance in Pulmonary Tuberculosis Patients
Rohmatika, J., Aisyah, P. S., & Gartika, N. (2024) · Journal of Health Sciences and Medical Development · doi:10.56741/hesmed.v3i02.595
Agarwal, N., Gogoi, H., Eeba, E., Augustin, L., Khan, M. Y., Kumar, Y., Bhowmick, S. K., & Dey, B. (2026) · eLife · doi:10.7554/elife.107025.3
Agarwal, N., Gogoi, H., Eeba, E., Augustin, L., Khan, M. Y., Kumar, Y., Bhowmick, S. K., & Dey, B. (2025) · eLife · doi:10.7554/elife.107025
Im, S., Gogolashvili, A., Gonzalez-Bocco, I. H., Allard, D. D., Urma, D., & Altamimi, S. A. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.140744
Kain, D. C., Lewinsohn, D. M., & Lewinsohn, D. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-94540-3_8
Espasa, M., Pagán, B., Fernández-Pittol, M., Orcau, À., Tudó, G., García, F., Martínez, J.-A., Soler, N., Horvath-Ruiz, L., Nicolás, L. S., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14090875
Magubane, N., & Shangase, S. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i9.1891
Song, C., Zhao, C.-Y., Huang, X., Mo, C.-J., Qiang, H.-B., Lin, X.-S., Huang, Z.-T., Xie, Z., & Zhu, Q. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s590648
Alvarez, S. N., & Peralta, M. I. (2025) · Journal of Medical Sciences and Interdisciplinary Research · doi:10.51847/vfpndetyjb
Bian, H., Li, T., Zhou, Y., Lu, W., Wang, R., Sun, Y., & Huang, G. (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102229
Adjunctive Multicomponent Crystals of Two Anti-Tubercular Drugs with Pyridoxine
Matlapeng, T. A., Geswindt, T. E., Walker, R. B., & Smith, V. J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030297
Ojha, S., Adhikari, A., Adhikari, S., Khanal, S., Kalwar, C. S., & Panta, O. P. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02460-25
- Authors
- Mase, S. R., & Chorba, T.
- Affiliations
- World Health Organization Regional Office for South-East Asia (IN)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Chorba, Terence
- Venue
- Clinics in Chest Medicine
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 40
- Issue
- 4
- Pages
- 775-795
- ISSN
- 0272-5231 (ISSN-L)
- PMC
- PMC7000172
- OpenAlex
- W2987479663
- Cited by
- 104
- References
- 33
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 14 · 2023: 20 · 2022: 17 · 2021: 14 · 2020: 6
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinics in Chest Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- World Health Organization
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Surgery › Diagnosis and treatment of tuberculosis
- Keywords
- drug-resistant tuberculosis, multidrug-resistant tuberculosis, TB treatment regimens, rapid molecular diagnostics, WHO treatment guidelines, treatment toxicity
- MeSH terms
- Antitubercular Agents, Humans, World Health Organization, Treatment Outcome, Tuberculosis, Multidrug-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
